MidWestOne Financial Group Inc. Purchases 307 Shares of IQVIA Holdings Inc. (NYSE:IQV)

MidWestOne Financial Group Inc. grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,554 shares of the medical research company’s stock after acquiring an additional 307 shares during the period. MidWestOne Financial Group Inc.’s holdings in IQVIA were worth $963,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in shares of IQVIA in the 2nd quarter valued at about $27,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter valued at about $29,000. Rise Advisors LLC bought a new position in shares of IQVIA in the 1st quarter valued at about $31,000. Finally, Riverview Trust Co bought a new position in shares of IQVIA in the 1st quarter valued at about $32,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $234.79 on Friday. The firm has a 50 day moving average of $241.49 and a 200-day moving average of $233.52. The stock has a market capitalization of $42.80 billion, a PE ratio of 32.08, a PEG ratio of 2.25 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. Robert W. Baird lifted their target price on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Royal Bank of Canada began coverage on shares of IQVIA in a report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 target price for the company. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price for the company. Finally, Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.